Compare McKesson Corporation (MCK) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Microsoft — how do they compare? McKesson Corporation trades at $899.06 (market cap $102.58B), while Microsoft trades at $498.71 (market cap $3.76T). The key difference: Microsoft is far larger — about 36.7× McKesson Corporation's market cap, and Microsoft pays the higher dividend (0.72%). Which is the better fit depends on your goals.
| MCK | MSFT | |
|---|---|---|
Market Cap | $102.58B | $3.76T |
Sector | Health | Technology |
52-Week High | $995.69 | $542.07 |
52-Week Low | $659.01 | $352.83 |
Enterprise Value | $109.12B | $3.74T |
Dividend Yield | 0.43% | 0.72% |
Volume | — | 36,654,621 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.
Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.
Microsoft (MSFT) trades at $506.06, up 1.21% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with $281.72B revenue, 40.31% net margin, and consistent earnings beats. Analyst consensus remains overwhelmingly positive with 80.49% buy ratings and $552.73 price target, representing 9.2% upside potential. Recent news highlights Microsoft's AI leadership and cloud computing strength.
Microsoft presents a compelling investment case with strong financial performance and AI-driven growth prospects. Key opportunities include Azure cloud expansion and Copilot adoption, while risks involve increased capital expenditures and competitive pressures. The stock's current valuation at 28.19 P/E appears reasonable given growth trajectory, though investors should monitor execution on AI investments and macroeconomic conditions affecting tech spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
